Ignite Creation Date:
2025-12-25 @ 2:04 AM
Ignite Modification Date:
2026-02-09 @ 3:10 PM
Study NCT ID:
NCT00742560
Status:
COMPLETED
Last Update Posted:
2018-01-10
First Post:
2008-08-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
Sponsor:
AbbVie (prior sponsor, Abbott)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-08
Start Date Type:
None
Primary Completion Date:
2016-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-10
Completion Date Type:
ACTUAL
First Submit Date:
2008-08-25
First Submit QC Date:
None
Study First Post Date:
2008-08-27
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-10-11
Results First Submit QC Date:
None
Results First Post Date:
2018-01-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-01-08
Last Update Post Date:
2018-01-10
Last Update Post Date Type:
ACTUAL